Multi-Organ Microphysiological Systems Targeting Specific Organs for Recapitulating Disease Phenotypes via Organ...

Prior research has shown that systemic metabolic diseases originate from sustained communication between diverse biological structures, often leading to severe functional deficits across multiple physiological networks. These conditions often lead to severe functional deficits across multiple physiological networks, including the endocrine and cardiovascular systems, which are difficult to replicate in vitro. Conventional in vitro models frequently fail to capture the intricate causal links between specific tissue microenvironments and systemic signaling, limiting our understanding of disease progression. Traditional approaches often overlook the dynamic nature of biochemical exchanges occurring between distant anatomical sites, such as the gut-liver axis, which are central to metabolic health. Existing platforms struggle to replicate the precise physiological conditions required to study complex disease etiologies and their progression over time without fluidic connectivity. Researchers have noted that the lack of fluidic connectivity in standard cell culture prevents the observation of systemic feedback loops and the identification of novel therapeutic targets. This absence of evidence motivated the exploration of more sophisticated engineering solutions to simulate human-scale organ interactions and capture the complexity of systemic metabolic diseases.

Researchers sought to evaluate how multi-organ microphysiological systems (MOMPS) replicate the complex interactions driving systemic metabolic disorders through controlled biochemical signaling. This investigation focuses on the capacity of these platforms to simulate diverse interorgan crosstalk within controlled environments, providing a more accurate portrayal of human organ interactions. The work examines how scalable biological complexity allows for a more authentic representation of human physiology compared to static models, which often fail to mimic systemic responses. Scientists intended to identify novel relationships between metabolic processes, immune responses, and organ-specific signaling pathways that contribute to the development of chronic diseases. The analysis explores the potential of these systems to enhance the efficiency of preclinical drug development and mechanistic research by providing high-fidelity human data. By leveraging state-of-the-art biofabrication, the study assesses the current technical capabilities and future challenges of pathological modeling in the context of systemic health. The authors aim to clarify how these microdevices can bridge the gap between simple cell cultures and complex animal models to improve clinical translation rates.

The review synthesizes data from platforms using advanced biofabrication technology to construct modular tissue interfaces that mimic the structural and functional properties of human organs. Engineering teams employed microfluidic circuits to establish fluidic connectivity between distinct cellular compartments representing the liver, gut, or adipose tissue, allowing for continuous nutrient and waste exchange. These multi-organ microphysiological systems (MOMPS) use precise flow control to mimic the hemodynamic forces present in the human vasculature, which are essential for maintaining cellular phenotype. Investigators analyzed the integration of sensors within these devices to monitor real-time metabolic flux and cytokine secretion, providing a dynamic view of cellular health. The methodology involves scaling biological components to ensure that the relative sizes of simulated organs reflect physiological proportions, maintaining the relevance of the model to human biology. Researchers compared different scaffolding materials used to maintain the structural integrity of three-dimensional (3D) tissue constructs while supporting the growth of multiple cell types. The study also evaluates the use of bioprinting to position multiple cell types within a single microfluidic chip, enhancing the complexity and realism of the model.

Multi-organ microphysiological systems (MOMPS) successfully recapitulate the pathological phenotypes of systemic metabolic diseases by facilitating bidirectional signaling between diverse tissue types. These platforms show that interorgan crosstalk significantly influences the progression of metabolic dysfunction and immune activation, providing insights into the systemic nature of these disorders. The integration of multiple tissue types allows for the observation of secondary organ failure triggered by primary metabolic insults, which is often impossible in single-organ models. Controlled interactions within these microdevices provide a higher degree of accuracy in predicting human responses than traditional animal models, which often exhibit different metabolic profiles. Data indicates that scalable representations of biological complexity enable the identification of previously unknown metabolic pathways and potential drug targets for treating chronic conditions. The review highlights that biofabricated models can simulate the tissue-specific microenvironments necessary for authentic disease manifestation, including the presence of extracellular matrix components. Findings suggest that these systems can replicate the chronic inflammatory states linked to prolonged metabolic stress, offering a new tool for studying systemic inflammation.

The implementation of multi-organ microphysiological systems (MOMPS) represents a transformative shift in the study of systemic pathologies by providing a more holistic view of human health. These engineering advancements offer a robust framework for investigating the molecular drivers of chronic metabolic conditions and identifying new therapeutic strategies. Future research should focus on increasing the throughput of these devices to accelerate the screening of novel therapeutic compounds and reduce the time to clinical trials. The authors suggest that refining biofabrication techniques will lead to more personalized medicine approaches using patient-derived cells to model individual disease responses. Enhanced preclinical studies using these systems could reduce the reliance on animal testing while improving clinical translation rates and patient safety. Integrating complex immune components into these models will likely reveal deeper insights into the inflammatory aspects of metabolic disease and the role of the immune system. The study concludes that these platforms are essential for understanding the systemic nature of human health and disease, paving the way for more effective treatments.